Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China

Abstract Objective Efgartigimod, a neonatal Fc receptor antagonist, facilitates antibody degradation including pathogenic IgGs. The ADAPT study demonstrated the tolerability and efficacy of efgartigimod in the treatment of generalized myasthenia gravis (gMG). However, very limited evidence is availa...

Cijeli opis

Bibliografski detalji

Glavni autori:	Sushan Luo, Qilong Jiang, Wenshuang Zeng, Qinzhou Wang, Zhangyu Zou, Yanyan Yu, Daojun Hong, Quantao Zeng, Song Tan, Zhouao Zhang, Yong Zhang, Xiuming Guo, Jing Chen, Zhongyan Zhao, Shixiong Huang, Jianquan Shi, Ying Chen, Lei Du, Chong Yan, Jianying Xi, Jie Song, Chongbo Zhao, the Chinese Myasthenia Gravis Collaborating Group (CMGCG)
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2024-08-01
Serija:	Annals of Clinical and Translational Neurology
Online pristup:	https://doi.org/10.1002/acn3.52142
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!